Body Pharm Tesamorelin 32 Pen: Buy Online UK — Full Research Guide 2026
The Body Pharm Tesamorelin 32 Pen is a pre-mixed, multi-dose subcutaneous research peptide device delivering 32 fixed actuations from a single cartridge — equivalent to a full 32-day daily-dose protocol. JCSG.org is your destination to order it now for UK research. Use the buy box above to add it to your cart and get it dispatched fast. Tesamorelin is a prescription-only medicine in the UK and is not scheduled under the Misuse of Drugs Act 1971. All products are sold for laboratory research use only.
Key Takeaways
- The Body Pharm Tesamorelin 32 Pen delivers 32 fixed doses from a single cartridge — order yours now via the buy box above on JCSG.org.
- Pre-filled pens eliminate reconstitution variables, making them ideal for standardised, repeated-dose protocols.
- Tesamorelin is a GHRH analogue with an FDA-approved clinical track record (Egrifta, 2010) for visceral fat reduction in HIV-associated lipodystrophy.
- Tesamorelin is not MHRA-licensed in the UK and carries no controlled-drug scheduling, but verify current regulatory status at the point of order.
- Request the batch certificate of analysis and product datasheet from JCSG.org before committing to a protocol.
This guide covers what "32 doses" means for protocol planning, how to evaluate the pen format against lyophilised vials, and the UK regulatory position on tesamorelin as a research chemical. Ready to order? Add the Body Pharm Tesamorelin 32 Pen to your cart now.
What Is the Body Pharm Tesamorelin 32 Pen?
The Body Pharm Tesamorelin 32 Pen is a pre-filled, multi-dose subcutaneous injection device containing synthetic tesamorelin. The "32" designation refers to the device delivering 32 individual pre-measured doses from a single pen, corresponding to a 32 mg total peptide load across the device. Body Pharm manufactures it and JCSG.org supplies it to UK researchers — order it directly via the buy box above.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH): a 44-amino-acid peptide modified with a trans-3-hexenoic acid group at the N-terminus to extend plasma half-life. For deeper biochemistry, mechanism of action, and assay data, see the tesamorelin peptide overview.
The Body Pharm Tesamorelin 32 Pen is available to order now on JCSG.org. See the current price in the buy box above — no need to look elsewhere. The 32 mg total load is the most consistent quantitative claim across product listings. For official manufacturer information, Body Pharm's own UK domain is bodypharm.co.uk.
The 32-pen architecture is not unique to tesamorelin within the Body Pharm catalogue. The same multi-dose pen format appears across the brand's product line, including the Body Pharm MOTS-C 32 Pen, which confirms 32-dose pens as a deliberate product-line standard rather than a tesamorelin-specific design.
What Does '32 Doses' Mean for a Research Protocol?
A 32-dose pen contains 32 fixed, pre-measured actuations from a single cartridge. A researcher administering one dose per day exhausts the device in 32 days (roughly 4.5 weeks). An alternate-day schedule extends coverage to approximately 64 days. The dose count is a hard ceiling set at manufacture. Unlike lyophilised vials, there is no reconstitution variable to manipulate the per-shot volume.
This matters for protocol planning because it determines how many pens a study will require. Published tesamorelin investigations, including the clinical trials underpinning the 2010 FDA approval of Egrifta for HIV-associated lipodystrophy, typically used daily 2 mg subcutaneous dosing over 26–52 weeks. A laboratory model mirroring that cadence would require six to twelve 32-dose pens to cover a single full-duration arm. That calculation must also account for wastage, priming losses, and replicate subjects. Stock up now on JCSG.org — use the buy box above to add multiple units to your order.
Mapping pen capacity to study length
The arithmetic is straightforward, but the mg-per-dose figure is the variable that determines whether the Body Pharm pen fits a target protocol. Dividing the 32 mg total load evenly across 32 doses yields 1 mg per actuation. Researchers targeting the 2 mg per actuation used in the Egrifta clinical literature should plan for two actuations per scheduled dose, which cuts the pen's working life to 16 days — factor this into multi-pen procurement through JCSG.org.
For confirmed per-dose volume and mg-per-actuation, request the batch certificate of analysis from JCSG.org at the time of order. See the current price for the Body Pharm Tesamorelin 32 Pen in the buy box above.
Tesamorelin as a GHRH Analogue: Mechanism Summary
Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-terminus to resist dipeptidyl peptidase-IV cleavage and extend plasma half-life relative to native GHRH(1–44). That stabilising modification differentiates it from sermorelin and other shorter GHRH fragments, and it is the structural feature most relevant to dose-frequency decisions in a research protocol.
The molecule binds GHRH receptors on somatotroph cells in the anterior pituitary, triggering pulsatile growth hormone release. This release retains the negative-feedback architecture of the somatotropic axis — the upstream point of action is the key methodological distinction from exogenous recombinant GH. Tesamorelin elevates endogenous GH and downstream insulin-like growth factor 1 (IGF-1) within physiological pulsatile patterns, rather than imposing a flat exogenous concentration curve.
GHRH receptor agonism is the primary mechanism of action, consistent with the 2010 FDA approval of Egrifta (Theratechnologies) for HIV-associated lipodystrophy.
Primary research endpoints
- Visceral adipose tissue (VAT) reduction is the most heavily characterised. The clinical trials that led to Egrifta's approval measured VAT as a primary outcome, and this endpoint dominates the lipodystrophy trial literature.
- Serum lipid fractions (triglycerides, non-HDL cholesterol) and lean mass changes via dual-energy X-ray absorptiometry (DEXA) are secondary endpoints tracked in those same trials.
- Cognitive and cerebrovascular endpoints are emerging research areas, though the supporting trial base is considerably thinner than for VAT.
Tesamorelin is a prescription-only medicine in the UK when supplied as an authorised drug product. It is not scheduled under the Misuse of Drugs Act 1971. Procurement for laboratory research use must comply with the supplier's stated research-use-only terms. Order the Body Pharm Tesamorelin 32 Pen on JCSG.org now.
Body Pharm Tesamorelin 32 Pen: Format & Specification
The table below summarises the key specification fields for the Body Pharm Tesamorelin 32 Pen available on JCSG.org. See the buy box above for the current live price.
| Specification | Detail |
|---|---|
| Dose count | 32 fixed actuations per pen |
| Total peptide load | 32 mg (third-party listing data; request CoA to confirm) |
| Format | Pre-filled, multi-dose subcutaneous pen |
| Storage | 2–8 °C, refrigerated, upright, shielded from direct light; do not freeze |
| Reconstitution required | No — pre-mixed, ready to use |
| Price | See current price in the buy box above on JCSG.org |
Add the Body Pharm Tesamorelin 32 Pen to your cart — order now on JCSG.org.
How to Evaluate Price per Dose
Price per dose is only meaningful when mg-per-dose is held constant. The most honest benchmark is price per mg of total peptide load:
Price per mg = Total pen price ÷ Total mg peptide load
Pre-filled pens also eliminate the consumables cost attached to lyophilised vials: bacteriostatic water, insulin syringes, and reconstitution time. Factor those line items into total cost of research before comparing formats. See the current JCSG.org price in the buy box above for the Body Pharm Tesamorelin 32 Pen.
Pre-Filled Pen vs Lyophilised Vial: Which Format for Research?
Pen format suits standardised, repeated-dose protocols. Lyophilised vials suit variable-dose or pilot studies. The choice depends on how fixed the dosing schedule is across the study.
Pre-filled pens remove reconstitution as a variable. There is no bacteriostatic water to source, no insulin syringe to draw, and no operator-introduced concentration error from inaccurate diluent volumes. Dose delivery is mechanical and repeatable. This matters when a protocol calls for 30+ identical administrations to a cohort and the research question is sensitive to dose variance. Workflow time per administration drops, and contamination risk falls in settings without a Grade A cabinet.
The trade-offs are real. The dose increment is fixed by the device, so free titration below that increment is not possible. Upfront cost per unit is higher than an equivalent vial. Once a pen is activated, the in-use window is shorter than a sealed lyophilised vial stored at 2–8 °C.
Lyophilised vials retain advantages for pilot work and dose-response studies. The researcher chooses the reconstitution volume, which sets the working concentration and allows any dose to be drawn within or below the pen's range. Unit cost can be lower when peptide-per-mg is benchmarked honestly, and unopened vials hold longer pre-reconstitution. Against that, every reconstitution is a manual step that introduces variability, and the consumables stack (bacteriostatic water, syringes, alcohol swabs, sharps disposal) needs costing into the total.
For standardised GH-axis research protocols, the Body Pharm Tesamorelin 32 Pen is the higher-consistency choice. Order it now on JCSG.org using the buy box above.
Storage and Stability Requirements
Tesamorelin is a 44-amino-acid peptide sensitive to heat, light, and freeze-thaw cycling. Any pre-mixed pen should be held refrigerated at 2–8 °C, kept upright, shielded from direct light, and never frozen. Freezing a solubilised GHRH analogue risks aggregation and loss of biological activity: ice crystal formation can disrupt the peptide's tertiary structure, and repeated excursions above 8 °C accelerate deamidation at asparagine and glutamine residues.
Request the batch certificate of analysis (CoA) and product insert directly from JCSG.org before committing to a cohort protocol. The CoA will confirm the in-use shelf life after first actuation, purity by HPLC, and any explicit light-protection requirements for the specific lot you receive.
UK Regulatory Position on Tesamorelin Research Chemicals (2026)
Tesamorelin holds no UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). UK vendors supply it strictly as a research chemical, not as a licensed medicine. The FDA approval of Egrifta (tesamorelin) for HIV-associated lipodystrophy, dated 2010, is a US clinical authorisation and confers no equivalent UK licensed-medicine status. Procurement teams should treat any cross-reference to Egrifta's US label as pharmacological background only.
Tesamorelin is not named as a controlled substance under the Misuse of Drugs Act 1971 or its current schedules, based on Home Office controlled-drugs lists reviewed through 2023–2025. Statutory instruments can amend schedules without long lead times. Verify the position against the most recent Home Office and MHRA publications at the point of order. Where tesamorelin is handled as a finished medicinal product, MHRA classification as a prescription-only medicine (POM) applies. The research-chemical supply chain sits outside that licensed route.
Research use only. The Body Pharm Tesamorelin 32 Pen is sold as a research chemical for laboratory use only. It is not an MHRA-licensed medicine. Nothing on this page constitutes medical advice or a recommendation for human administration. Verify current MHRA and Home Office guidance before procurement.
Order the Body Pharm Tesamorelin 32 Pen on JCSG.org
JCSG.org is the place to buy the Body Pharm Tesamorelin 32 Pen in the UK. The current price is shown live in the buy box at the top of this page. Add your units to the cart and check out directly — order now. For questions about the product, batch CoA, or delivery, contact JCSG.org support via the site.
Related Body Pharm Pen Formats on JCSG UK
The Body Pharm 32-pen format is a standardised cartridge geometry used across several peptides in the same product line. This simplifies parallel protocol design when dose-volume calibration has already been validated on one device. Researchers running GH-axis work alongside metabolic or mitochondrial endpoints often find it efficient to keep the device class constant across arms. Browse and buy all formats below:
- Body Pharm MOTS-C 32 Pen
- Body Pharm NAD+ 1000 Pen
- Body Pharm Tirzepatide 30 Pen
- Body Pharm Tirzepatide 60 Pen
- Body Pharm Semaglutide 6 Pen
Next Steps
Order the Body Pharm Tesamorelin 32 Pen on JCSG.org now — use the buy box above to check the current price and add it to your cart. Before running your protocol, request the batch certificate of analysis and product datasheet from JCSG.org to confirm the per-dose mg, total peptide load, and in-use storage window. Cross-check the current MHRA and Home Office regulatory position on tesamorelin at the point of procurement. For the underlying pharmacology and receptor-binding data that inform dose selection, consult the tesamorelin peptide overview.
